Aeromonas Infections: Mechanisms, Virulence, and Immune Response

Aeromonas bacteria use a layered arsenal of toxins, secretion systems, and surface structures to colonize tissue, damage cells, and dodge immune defenses. The genus includes more than 30 species that live naturally in freshwater and soil, with A. hydrophila, A. caviae, and A. veronii biovar sobria responsible for most human infections.¹ These infections range from self-limiting diarrhea to rapidly fatal soft-tissue destruction, and understanding how the bacterium pulls this off requires looking at each layer of its attack and the immune machinery it provokes and subverts.

Where Aeromonas Lives and Who It Targets

Aeromonas thrives in freshwater lakes, rivers, and estuaries, but it also turns up in soil, vegetables, seafood, and treated drinking water. That breadth of habitat means exposure is common, yet clinical infections are relatively uncommon because a healthy immune system usually handles ingested or wound-introduced bacteria before they gain a foothold. The people who develop serious disease tend to share certain traits: chronic liver disease, malignancy, iron-overload conditions, or other states of immunosuppression.² Deferoxamine therapy for iron overload, for example, has been specifically linked to severe Aeromonas bloodstream infections because the drug provides the bacteria with a ready iron source that fuels their growth.³

Still, healthy people are not completely exempt. Cases of Aeromonas gastroenteritis in immunocompetent adults do occur, sometimes linked to travel, restaurant dining, or recent antibiotic use that disrupts normal gut flora.⁴ In one study of traveler’s diarrhea, half the patients with Aeromonas-positive stools had fever and abdominal cramps, and roughly half experienced persistent diarrhea lasting more than two weeks.⁵

Gaining a Foothold With Flagella and Biofilms

Before Aeromonas can secrete toxins or trigger immune chaos, it first has to stick to host tissue. The bacterium uses two distinct types of flagella to accomplish this. A single polar flagellum propels it through liquid, and multiple lateral flagella help it swarm across surfaces. Both types double as adhesins, physically latching onto gut lining cells. In laboratory experiments, strains that lost their polar flagellum were essentially unable to attach to intestinal cell lines, while losing the lateral flagellum cut attachment by about 60% compared to the wild-type bacterium.⁶

These flagella also help Aeromonas form biofilms, the sticky bacterial communities that resist both immune attack and antibiotics. Mutants lacking either flagellum type formed biofilms at least 30% less efficiently than wild-type strains.⁶ Biofilm formation is a practical concern because it helps the bacteria persist on medical devices, wound surfaces, and environmental reservoirs, making infections harder to clear once established.

The Toxin Arsenal

Once attached, Aeromonas deploys a suite of toxins and effector proteins. Three secretion systems, labeled type II, type III, and type VI, serve as the molecular syringes that deliver these weapons either into the surrounding environment or directly into host cells.

Aerolysin and the Pore-Forming Strategy

The best-studied Aeromonas toxin is aerolysin, a pore-forming protein. The bacterium secretes it as a soluble molecule that binds to the outer surface of a host cell membrane, clusters together with other aerolysin molecules, and assembles into a ring-shaped pore that punches through the membrane. Water and ions flood through these pores uncontrollably, and the cell swells and dies from osmotic lysis.⁷ Aerolysin binds membranes with strikingly high affinity; experiments measuring the earliest stages of membrane attachment detected binding at concentrations as low as 20 femtomolar, a vanishingly small amount that underscores how efficiently even trace quantities of the toxin can begin damaging cells.⁸

Act and the Inflammatory Cascade

A related toxin called Act (aerolysin-related cytotoxic enterotoxin) has broader effects. Beyond bursting red blood cells and killing cultured cells, Act triggers macrophages to produce proinflammatory cytokines and activates the arachidonic acid pathway, generating signaling molecules like prostaglandin E2 that amplify local inflammation.⁹ This means Act does not just kill cells directly; it also hijacks the immune system’s own inflammatory signals, causing collateral tissue damage. When researchers knocked out the gene encoding Act in Aeromonas, the resulting culture filtrates caused no visible damage to mouse intestinal lining, whereas filtrates from normal Aeromonas completely destroyed the microvilli.¹⁰ That stark difference confirmed Act as a central driver of gut tissue injury.

Type VI Secretion and Direct Injection

The type VI secretion system (T6SS) works differently from secreted toxins. It functions like a molecular spear, requiring direct contact between the bacterium and the host cell to deliver its payload. One of its key effectors, VgrG1, enters the host cell and chemically modifies actin, the structural protein that gives cells their shape and ability to move. By attaching a chemical group to actin through a process called ADP ribosylation, VgrG1 disrupts the entire internal skeleton of the cell, leading to rounding, detachment, and death.¹¹ Other effectors travel through the type III secretion system, which works on a similar inject-on-contact principle. The most virulent Aeromonas strains tend to carry combinations of these secretion system effectors alongside cytotoxic enterotoxin, and that cocktail determines whether a given strain causes mild illness or life-threatening deep-tissue infection.¹²

Quorum Sensing as a Virulence Coordinator

Aeromonas does not release its full weapon set all the time. Instead, the bacteria communicate with each other through a chemical signaling system. Individual bacteria produce and release small signal molecules, and as the population grows, these molecules accumulate. Once the concentration reaches a threshold, gene expression shifts and the bacteria begin producing enzymes and toxins in concert. In A. hydrophila, the signal molecule is a compound called C4-HSL, produced by the AhyI enzyme. When researchers disabled the gene for AhyI, the bacteria stopped making C4-HSL, and their production of proteases (enzymes that break down host proteins) dropped dramatically. Adding C4-HSL back to the culture restored protease activity.¹³

This coordination means that Aeromonas does not waste resources producing tissue-degrading enzymes when bacterial numbers are low and the effort would be futile. It waits until the colony is large enough to mount a concerted attack. From a treatment standpoint, disrupting quorum sensing is an appealing target because shutting down the communication channel could disarm virulence without necessarily killing the bacteria, reducing the selective pressure for antibiotic resistance.

How the Immune System Responds

When Aeromonas toxins begin damaging tissue, the innate immune system is the first line of defense. Macrophages detect bacterial components and toxin activity through intracellular sensor complexes called inflammasomes. Research on A. veronii showed that infection of mouse macrophages activated caspase-1 through both NLRP3 and NLRC4 inflammasome pathways, depending on which virulence factor triggered the alarm. Aerolysin triggered NLRP3, while the type III secretion system activated NLRC4. The result was release of the proinflammatory cytokine IL-1β and a form of inflammatory cell death called pyroptosis.¹⁴

Pyroptosis is a double-edged sword. When a macrophage undergoes pyroptosis, it bursts open and dumps its inflammatory contents into the surrounding tissue, recruiting more immune cells and amplifying the local response. That alarm bell helps contain the infection, but it can also cause substantial bystander tissue damage, especially when large numbers of bacteria are triggering the response simultaneously. Similar inflammasome activation through NLRP3 has been confirmed in macrophages infected with A. hydrophila, reinforcing that this is a shared response across the major disease-causing Aeromonas species.¹⁵

How Aeromonas Evades Immune Killing

The complement system is one of the fastest-acting immune weapons against bacteria in the bloodstream. It tags bacterial surfaces with proteins that attract immune cells and punch holes in bacterial membranes. Aeromonas has evolved at least two strategies to block this process.

The first involves the bacterium’s outer coat of sugar chains called O-antigen lipopolysaccharide. Strains that possess a full-length O-antigen layer shield the outer membrane proteins that would otherwise bind C1q, the protein that initiates the complement cascade. With C1q unable to dock, the cascade never starts, and the bacterium resists killing by serum. Strains lacking this O-antigen shield bind C1q readily and are killed.¹⁶

The second strategy is more active. A surface lipoprotein called TagA cleaves C1-inhibitor (C1-INH), a regulatory protein the host uses to control complement activation. By degrading C1-INH on the bacterial surface, Aeromonas prevents the host from mounting complement-mediated lysis of the bacterium itself. When researchers deleted the TagA gene, the mutant bacterium could no longer cleave C1-INH and became significantly more sensitive to killing by serum.¹⁷ Together, these mechanisms explain why certain Aeromonas strains survive well in the bloodstream while others are quickly cleared.

Clinical Picture Beyond the Gut

The most common human Aeromonas infection is gastroenteritis, typically presenting as watery diarrhea that can be accompanied by cramping abdominal pain, fever, and malaise.⁴ But the infections that make clinicians lose sleep are the extraintestinal ones, particularly necrotizing fasciitis. Aeromonas-driven necrotizing fasciitis is rare but extraordinarily aggressive. In a published case, a 39-year-old man with alcoholic liver cirrhosis developed necrotizing fasciitis caused by A. hydrophila that spread from his legs to his upper limbs and trunk within 24 hours despite emergency surgical debridement and bilateral above-knee amputation. He died of septic shock and organ failure within 48 hours of arriving at the hospital.¹⁸

A retrospective analysis of Aeromonas necrotizing fasciitis cases over 18 years identified bloodstream infection, shock, visible skin necrosis at presentation, and initial treatment with ineffective antibiotics as independent predictors of death.¹⁹ The takeaway for clinicians is that antibiotic choice in the first hours matters enormously. Unfortunately, Aeromonas carries intrinsic resistance to several commonly prescribed antibiotics, which complicates empirical therapy.

An Unexpected Infection Route Through Medicinal Leeches

Surgeons use medicinal leeches to reduce blood congestion in tissue flaps and reattached fingers, and Aeromonas is the most frequent infectious complication of this procedure.²⁰ Leeches naturally harbor Aeromonas in their gut as symbiotic bacteria, and the organisms are introduced directly into the wound during feeding. Resulting infections can range from localized wound infections to tissue-flap loss and sepsis, sometimes undermining the very reconstructive surgery the leeches were meant to support.²¹ Prophylactic antibiotics before and during leech therapy are now standard practice, though the emergence of multidrug-resistant Aeromonas strains complicates antibiotic selection for this purpose.²²

Antibiotic Resistance and the Carbapenem Problem

Aeromonas species carry chromosomal genes encoding resistance to several beta-lactam antibiotics, and the most clinically worrying of these is the CphA metallo-beta-lactamase, which specifically breaks down carbapenems. Carbapenems are considered last-resort drugs for many serious infections, so intrinsic resistance to them in a common waterborne organism is a real concern. In one Australian survey, the CphA gene was present in 100% of A. veronii isolates, 90% of A. hydrophila, and about 87% of A. dhakensis, though it was absent in A. caviae.²³ The CphA enzyme is inducible, meaning it ramps up production when the bacterium senses beta-lactam antibiotics in its environment.²⁴

Beyond chromosomal resistance, Aeromonas readily acquires new resistance genes through horizontal gene transfer. Conjugation, the direct passing of genetic material between bacteria, is a primary route by which mobile genetic elements carrying resistance genes spread through Aeromonas populations in aquatic environments.²⁵ Because Aeromonas occupies the same water systems that receive agricultural runoff and wastewater carrying antibiotics and resistant bacteria, it acts as both a recipient and a reservoir of resistance genes that can be shared more broadly across bacterial communities.

Identifying Aeromonas in the Lab

Historically, pinning down which Aeromonas species is causing an infection was difficult because the species look similar under standard biochemical tests, and some species were often misidentified. Protein profiling by mass spectrometry (MALDI-TOF MS) has changed this. In a comparison study, MALDI-TOF correctly identified about 92% of clinical Aeromonas isolates to the species level and another 6% to the genus level.²⁶ Gene sequencing remained the most accurate method overall, but MALDI-TOF is fast enough for routine clinical use and has made species-level identification practical in hospital laboratories. Accurate species identification matters because different species carry different resistance profiles, as illustrated by the variable distribution of CphA, and appropriate antibiotic selection depends on knowing exactly which species you are dealing with.

Aeromonas in Fish and the One Health Connection

Aeromonas is not just a human pathogen. In aquaculture, it is one of the most economically damaging bacterial pathogens of freshwater fish. The disease it causes in fish, called motile Aeromonas septicemia (MAS), produces hemorrhagic lesions, fin rot, and internal organ damage that can kill large numbers of fish in a short time.²⁷ Experimental waterborne challenges with virulent A. hydrophila in channel catfish reproduced the reddened fins, septicemia, and eye hemorrhaging seen in natural outbreaks.²⁸

The aquaculture angle matters for human health because antibiotics are widely used in fish farming to control Aeromonas outbreaks, and this heavy antibiotic use selects for resistant strains. Resistance genes found in Aeromonas from aquatic animals, such as those encoding TEM-type beta-lactamases and tetracycline resistance, are the same genes found in human clinical isolates, illustrating how resistance moves between environments and species.²⁹ This overlap is a textbook example of the One Health framework in action: what happens to bacteria in a catfish pond has consequences for a patient in an intensive care unit who needs a carbapenem to work.